TNM classification and the need for revision of pN3a breast cancer
Abstract Background According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether progn...
Gespeichert in:
Veröffentlicht in: | European journal of cancer (1990) 2017-07, Vol.79, p.23-30 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 30 |
---|---|
container_issue | |
container_start_page | 23 |
container_title | European journal of cancer (1990) |
container_volume | 79 |
creator | van Nijnatten, T.J.A Moossdorff, M de Munck, L Goorts, B Vane, M.L.G Keymeulen, K.B.M.I Beets-Tan, R.G.H Lobbes, M.B.I Smidt, M.L |
description | Abstract Background According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether prognosis of pN3a based on at least an infraclavicular LNM differs from ≥10 axillary LNMs. Methods Data were obtained from the Netherlands Cancer Registry. All patients were diagnosed between 2005 and 2008 with primary invasive epithelial breast cancer and pN2a or pN3a status as pathologic result. Patients with pN3a were subdivided in pN3a based on at least an infraclavicular LNM or ≥10 axillary LNMs. Disease-free survival (DFS) included any local, regional or contralateral recurrence, distant metastasis or death within 5 years. Kaplan–Meier curves provided information on 5-year DFS and 8-year overall survival (OS). In addition, Cox proportional hazards model was used to measure the effect of relevant clinicopathological variables on DFS and OS. Results A total of 3400 patients with pN2a and 1788 patients with pN3a were included. In 83 patients, pN3a was based on at least an infraclavicular LNM (4.6%) and in 1705 patients because of ≥10 axillary LNMs (95.4%). After multivariable analyses, DFS and OS were inferior in patients with pN3a based on ≥10 axillary LNMs compared to infraclavicular LNM (DFS 48.8% versus 63.8%, hazard ratio [HR] 1.59, p = 0.036; OS 46.6% versus 63.9%, HR 1.46, p = 0.042). Furthermore, pN2a and pN3a based on infraclavicular LNM had comparable DFS and OS. Conclusion PN3a status based on an at least an infraclavicular LNM is rare, yet its prognosis is superior to ≥10 axillary LNMs. Reclassification of infraclavicular LNM in the next TNM should therefore be considered into pN2a. |
doi_str_mv | 10.1016/j.ejca.2017.04.002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1893971778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804917308791</els_id><sourcerecordid>1893971778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-f1e3874aa9cd2e61fa6fbb7e63bbd26726b8fb6ed2d0bd950022b0f024c78ca63</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EotvCH-CAInHhkjD-2NiWEFKpKCCVcqCcLX-MhUM2Wexspf57HG3poQdOPvh5RzPPS8grCh0F2r8bOhy87RhQ2YHoANgTsqFK6hbUlj0lG9Bb3SoQ-oScljIAgFQCnpMTpsRWUao35OPN9bfGj7aUFJO3S5qnxk6hWX5hMyGGJs65yXibyvozx2Z_zW3jMtqyNN5OHvML8izaseDL-_eM_Lz8dHPxpb36_vnrxflV6wXXSxspciWFtdoHhj2Nto_OSey5c4H1kvVORddjYAFc0Nt6DnMQgQkvlbc9PyNvj3P3ef5zwLKYXSoex9FOOB-KoUpzLamUqqJvHqHDfMhT3c4w4Ez0XFNaKXakfJ5LyRjNPqedzXeGglkNm8Gshs1q2IAwdaUaen0_-uB2GB4i_5RW4P0RwOriNmE2xSesokLK6BcT5vT_-R8exf2YplrN-BvvsDzcQU1hBsyPteO1Yio51Oop_wuHvZ-p</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2032463911</pqid></control><display><type>article</type><title>TNM classification and the need for revision of pN3a breast cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>van Nijnatten, T.J.A ; Moossdorff, M ; de Munck, L ; Goorts, B ; Vane, M.L.G ; Keymeulen, K.B.M.I ; Beets-Tan, R.G.H ; Lobbes, M.B.I ; Smidt, M.L</creator><creatorcontrib>van Nijnatten, T.J.A ; Moossdorff, M ; de Munck, L ; Goorts, B ; Vane, M.L.G ; Keymeulen, K.B.M.I ; Beets-Tan, R.G.H ; Lobbes, M.B.I ; Smidt, M.L</creatorcontrib><description>Abstract Background According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether prognosis of pN3a based on at least an infraclavicular LNM differs from ≥10 axillary LNMs. Methods Data were obtained from the Netherlands Cancer Registry. All patients were diagnosed between 2005 and 2008 with primary invasive epithelial breast cancer and pN2a or pN3a status as pathologic result. Patients with pN3a were subdivided in pN3a based on at least an infraclavicular LNM or ≥10 axillary LNMs. Disease-free survival (DFS) included any local, regional or contralateral recurrence, distant metastasis or death within 5 years. Kaplan–Meier curves provided information on 5-year DFS and 8-year overall survival (OS). In addition, Cox proportional hazards model was used to measure the effect of relevant clinicopathological variables on DFS and OS. Results A total of 3400 patients with pN2a and 1788 patients with pN3a were included. In 83 patients, pN3a was based on at least an infraclavicular LNM (4.6%) and in 1705 patients because of ≥10 axillary LNMs (95.4%). After multivariable analyses, DFS and OS were inferior in patients with pN3a based on ≥10 axillary LNMs compared to infraclavicular LNM (DFS 48.8% versus 63.8%, hazard ratio [HR] 1.59, p = 0.036; OS 46.6% versus 63.9%, HR 1.46, p = 0.042). Furthermore, pN2a and pN3a based on infraclavicular LNM had comparable DFS and OS. Conclusion PN3a status based on an at least an infraclavicular LNM is rare, yet its prognosis is superior to ≥10 axillary LNMs. Reclassification of infraclavicular LNM in the next TNM should therefore be considered into pN2a.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2017.04.002</identifier><identifier>PMID: 28458119</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Axilla ; Breast cancer ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer ; Classification ; Clavicle ; Combined Modality Therapy - methods ; Combined Modality Therapy - mortality ; Female ; Hazards ; Hematology, Oncology and Palliative Medicine ; Humans ; Invasiveness ; Kaplan-Meier Estimate ; Lymph node ; Lymph Node Excision - methods ; Lymph Node Excision - mortality ; Lymph nodes ; Lymphatic Metastasis ; Lymphatic system ; Medical prognosis ; Metastases ; Middle Aged ; Neoplasm Staging ; Netherlands - epidemiology ; Patients ; Prognosis ; Radiotherapy, Adjuvant - methods ; Radiotherapy, Adjuvant - mortality ; Reclassification ; Statistical models ; Survival ; Tumor Burden ; Tumors ; Womens health</subject><ispartof>European journal of cancer (1990), 2017-07, Vol.79, p.23-30</ispartof><rights>Elsevier Ltd</rights><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Jul 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-f1e3874aa9cd2e61fa6fbb7e63bbd26726b8fb6ed2d0bd950022b0f024c78ca63</citedby><cites>FETCH-LOGICAL-c439t-f1e3874aa9cd2e61fa6fbb7e63bbd26726b8fb6ed2d0bd950022b0f024c78ca63</cites><orcidid>0000-0002-6431-3538</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0959804917308791$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28458119$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Nijnatten, T.J.A</creatorcontrib><creatorcontrib>Moossdorff, M</creatorcontrib><creatorcontrib>de Munck, L</creatorcontrib><creatorcontrib>Goorts, B</creatorcontrib><creatorcontrib>Vane, M.L.G</creatorcontrib><creatorcontrib>Keymeulen, K.B.M.I</creatorcontrib><creatorcontrib>Beets-Tan, R.G.H</creatorcontrib><creatorcontrib>Lobbes, M.B.I</creatorcontrib><creatorcontrib>Smidt, M.L</creatorcontrib><title>TNM classification and the need for revision of pN3a breast cancer</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Abstract Background According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether prognosis of pN3a based on at least an infraclavicular LNM differs from ≥10 axillary LNMs. Methods Data were obtained from the Netherlands Cancer Registry. All patients were diagnosed between 2005 and 2008 with primary invasive epithelial breast cancer and pN2a or pN3a status as pathologic result. Patients with pN3a were subdivided in pN3a based on at least an infraclavicular LNM or ≥10 axillary LNMs. Disease-free survival (DFS) included any local, regional or contralateral recurrence, distant metastasis or death within 5 years. Kaplan–Meier curves provided information on 5-year DFS and 8-year overall survival (OS). In addition, Cox proportional hazards model was used to measure the effect of relevant clinicopathological variables on DFS and OS. Results A total of 3400 patients with pN2a and 1788 patients with pN3a were included. In 83 patients, pN3a was based on at least an infraclavicular LNM (4.6%) and in 1705 patients because of ≥10 axillary LNMs (95.4%). After multivariable analyses, DFS and OS were inferior in patients with pN3a based on ≥10 axillary LNMs compared to infraclavicular LNM (DFS 48.8% versus 63.8%, hazard ratio [HR] 1.59, p = 0.036; OS 46.6% versus 63.9%, HR 1.46, p = 0.042). Furthermore, pN2a and pN3a based on infraclavicular LNM had comparable DFS and OS. Conclusion PN3a status based on an at least an infraclavicular LNM is rare, yet its prognosis is superior to ≥10 axillary LNMs. Reclassification of infraclavicular LNM in the next TNM should therefore be considered into pN2a.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Axilla</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer</subject><subject>Classification</subject><subject>Clavicle</subject><subject>Combined Modality Therapy - methods</subject><subject>Combined Modality Therapy - mortality</subject><subject>Female</subject><subject>Hazards</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Invasiveness</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymph node</subject><subject>Lymph Node Excision - methods</subject><subject>Lymph Node Excision - mortality</subject><subject>Lymph nodes</subject><subject>Lymphatic Metastasis</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Netherlands - epidemiology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Radiotherapy, Adjuvant - methods</subject><subject>Radiotherapy, Adjuvant - mortality</subject><subject>Reclassification</subject><subject>Statistical models</subject><subject>Survival</subject><subject>Tumor Burden</subject><subject>Tumors</subject><subject>Womens health</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EotvCH-CAInHhkjD-2NiWEFKpKCCVcqCcLX-MhUM2Wexspf57HG3poQdOPvh5RzPPS8grCh0F2r8bOhy87RhQ2YHoANgTsqFK6hbUlj0lG9Bb3SoQ-oScljIAgFQCnpMTpsRWUao35OPN9bfGj7aUFJO3S5qnxk6hWX5hMyGGJs65yXibyvozx2Z_zW3jMtqyNN5OHvML8izaseDL-_eM_Lz8dHPxpb36_vnrxflV6wXXSxspciWFtdoHhj2Nto_OSey5c4H1kvVORddjYAFc0Nt6DnMQgQkvlbc9PyNvj3P3ef5zwLKYXSoex9FOOB-KoUpzLamUqqJvHqHDfMhT3c4w4Ez0XFNaKXakfJ5LyRjNPqedzXeGglkNm8Gshs1q2IAwdaUaen0_-uB2GB4i_5RW4P0RwOriNmE2xSesokLK6BcT5vT_-R8exf2YplrN-BvvsDzcQU1hBsyPteO1Yio51Oop_wuHvZ-p</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>van Nijnatten, T.J.A</creator><creator>Moossdorff, M</creator><creator>de Munck, L</creator><creator>Goorts, B</creator><creator>Vane, M.L.G</creator><creator>Keymeulen, K.B.M.I</creator><creator>Beets-Tan, R.G.H</creator><creator>Lobbes, M.B.I</creator><creator>Smidt, M.L</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6431-3538</orcidid></search><sort><creationdate>20170701</creationdate><title>TNM classification and the need for revision of pN3a breast cancer</title><author>van Nijnatten, T.J.A ; Moossdorff, M ; de Munck, L ; Goorts, B ; Vane, M.L.G ; Keymeulen, K.B.M.I ; Beets-Tan, R.G.H ; Lobbes, M.B.I ; Smidt, M.L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-f1e3874aa9cd2e61fa6fbb7e63bbd26726b8fb6ed2d0bd950022b0f024c78ca63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Axilla</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer</topic><topic>Classification</topic><topic>Clavicle</topic><topic>Combined Modality Therapy - methods</topic><topic>Combined Modality Therapy - mortality</topic><topic>Female</topic><topic>Hazards</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Invasiveness</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymph node</topic><topic>Lymph Node Excision - methods</topic><topic>Lymph Node Excision - mortality</topic><topic>Lymph nodes</topic><topic>Lymphatic Metastasis</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Netherlands - epidemiology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Radiotherapy, Adjuvant - methods</topic><topic>Radiotherapy, Adjuvant - mortality</topic><topic>Reclassification</topic><topic>Statistical models</topic><topic>Survival</topic><topic>Tumor Burden</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Nijnatten, T.J.A</creatorcontrib><creatorcontrib>Moossdorff, M</creatorcontrib><creatorcontrib>de Munck, L</creatorcontrib><creatorcontrib>Goorts, B</creatorcontrib><creatorcontrib>Vane, M.L.G</creatorcontrib><creatorcontrib>Keymeulen, K.B.M.I</creatorcontrib><creatorcontrib>Beets-Tan, R.G.H</creatorcontrib><creatorcontrib>Lobbes, M.B.I</creatorcontrib><creatorcontrib>Smidt, M.L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Nijnatten, T.J.A</au><au>Moossdorff, M</au><au>de Munck, L</au><au>Goorts, B</au><au>Vane, M.L.G</au><au>Keymeulen, K.B.M.I</au><au>Beets-Tan, R.G.H</au><au>Lobbes, M.B.I</au><au>Smidt, M.L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TNM classification and the need for revision of pN3a breast cancer</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>79</volume><spage>23</spage><epage>30</epage><pages>23-30</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Abstract Background According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether prognosis of pN3a based on at least an infraclavicular LNM differs from ≥10 axillary LNMs. Methods Data were obtained from the Netherlands Cancer Registry. All patients were diagnosed between 2005 and 2008 with primary invasive epithelial breast cancer and pN2a or pN3a status as pathologic result. Patients with pN3a were subdivided in pN3a based on at least an infraclavicular LNM or ≥10 axillary LNMs. Disease-free survival (DFS) included any local, regional or contralateral recurrence, distant metastasis or death within 5 years. Kaplan–Meier curves provided information on 5-year DFS and 8-year overall survival (OS). In addition, Cox proportional hazards model was used to measure the effect of relevant clinicopathological variables on DFS and OS. Results A total of 3400 patients with pN2a and 1788 patients with pN3a were included. In 83 patients, pN3a was based on at least an infraclavicular LNM (4.6%) and in 1705 patients because of ≥10 axillary LNMs (95.4%). After multivariable analyses, DFS and OS were inferior in patients with pN3a based on ≥10 axillary LNMs compared to infraclavicular LNM (DFS 48.8% versus 63.8%, hazard ratio [HR] 1.59, p = 0.036; OS 46.6% versus 63.9%, HR 1.46, p = 0.042). Furthermore, pN2a and pN3a based on infraclavicular LNM had comparable DFS and OS. Conclusion PN3a status based on an at least an infraclavicular LNM is rare, yet its prognosis is superior to ≥10 axillary LNMs. Reclassification of infraclavicular LNM in the next TNM should therefore be considered into pN2a.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28458119</pmid><doi>10.1016/j.ejca.2017.04.002</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6431-3538</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0959-8049 |
ispartof | European journal of cancer (1990), 2017-07, Vol.79, p.23-30 |
issn | 0959-8049 1879-0852 |
language | eng |
recordid | cdi_proquest_miscellaneous_1893971778 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Axilla Breast cancer Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer Classification Clavicle Combined Modality Therapy - methods Combined Modality Therapy - mortality Female Hazards Hematology, Oncology and Palliative Medicine Humans Invasiveness Kaplan-Meier Estimate Lymph node Lymph Node Excision - methods Lymph Node Excision - mortality Lymph nodes Lymphatic Metastasis Lymphatic system Medical prognosis Metastases Middle Aged Neoplasm Staging Netherlands - epidemiology Patients Prognosis Radiotherapy, Adjuvant - methods Radiotherapy, Adjuvant - mortality Reclassification Statistical models Survival Tumor Burden Tumors Womens health |
title | TNM classification and the need for revision of pN3a breast cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T01%3A53%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TNM%20classification%20and%20the%20need%20for%20revision%20of%20pN3a%20breast%20cancer&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=van%20Nijnatten,%20T.J.A&rft.date=2017-07-01&rft.volume=79&rft.spage=23&rft.epage=30&rft.pages=23-30&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2017.04.002&rft_dat=%3Cproquest_cross%3E1893971778%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2032463911&rft_id=info:pmid/28458119&rft_els_id=S0959804917308791&rfr_iscdi=true |